Immunotherapy progress in mismatch repair-deficient colorectal cancer and future therapeutic challenges

Cancer Journal (United States)

Volumn 22, Issue 3, 2016, Pages 190-195

  Link, James T ^a   Overman, Michael James ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Immune checkpoint; Microsatellite instability; Mismatch repair deficiency

Indexed keywords

BCG VACCINE; MISMATCH REPAIR PROTEIN PMS2; NIVOLUMAB; PEMBROLIZUMAB; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TICILIMUMAB; TUMOR CELL VACCINE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; DISEASE FREE SURVIVAL; GENE DOSAGE; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNOSURVEILLANCE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATION RATE; MUTATIONAL LOAD; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SOMATIC MUTATION; TUMOR MICROENVIRONMENT; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MUTATION; PATHOLOGY; PROCEDURES;

ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOTHERAPY; MICROSATELLITE INSTABILITY; MUTATION; TUMOR MICROENVIRONMENT;

EID: 84978204197     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000196     Document Type: Review

References (42)

1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61.
2. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.
3. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatchrepair deficiency. N Engl JMed. 2015;372:2509-2520.
4. Kroemer G, Galluzzi L, Zitvogel L, et al. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology. 2015;4. e1058597.
5. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.
6. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350-1356.
7. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58: 5248-5257.
8. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review:DNAtesting strategies aimed at reducingmorbidity andmortality from Lynch syndrome. Genet Med. 2009;11:42-65.
9. Haraldsdottir S, Hampel H, Tomsic J, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014;147:1308-1316e1301.
10. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-268.
11. Guastadisegni C, Colafranceschi M, Ottini L, et al.Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer. 2010;46:2788-2798.
12. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266-273.
13. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219-3226.
14. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623-4632.
15. Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014;25:1032-1038.
16. Lal N, Beggs AD, Willcox BE, et al. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology. 2015;4:e976052.
17. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353: 2654-2666.
18. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
19. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610-618.
20. Llosa NJ, CruiseM, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counterinhibitory checkpoints. Cancer Discov. 2015;5:43-51.
21. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3 - potential mechanisms of action. Nat Rev Immunol. 2015;15:45-56.
22. Brannon AR, Vakiani E, Sylvester BE, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 2014;15:454.
23. Stremitzer S, Sunakawa Y, Zhang W, et al. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. Pharmacogenomics J. 2015;15: 521-529.
24. Oh DY, Venook AP, Fong L. On the verge: immunotherapy for colorectal carcinoma. J Natl Compr Canc Netw. 2015;13:970-978.
25. Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18:148-157.
26. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353:345-350.
27. deWeger VA, Turksma AW, Voorham QJ, et al. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellitestable and microsatellite-instable colon cancer. Clin Cancer Res. 2012;18: 882-889.
28. TurksmaAW, CoupeVM, ShamierMC, et al. Extent and location of tumorinfiltrating lymphocytes in microsatellite-stable colon cancer predict outcome to adjuvant active specific immunotherapy. Clin Cancer Res. 2016; 22:346-356.
29. Uyl-deGroot CA, Vermorken JB, HannaMGJr, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005;23: 2379-2387.
30. Kloor M, Reuschenback M, Karback J, et al. Vaccination of MSI-H colorectal cancer patients with frameshift peptide antigens: a phase I/IIA clinical trial. ASCOAnnual Meeting. J ClinOncol. 2015;33:3020.
31. Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic Tlymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010; 28:3485-3490.
32. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
33. Brahmer JR, Drake CG,Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.J ClinOncol. 2010;28:3167-3175.
34. Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression offtreatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19:462-468.
35. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366: 2443-2454.
36. O'Neill B, Wallmark J, Lorente D, et al. Pembrolizuma (MK-3475) for patients with advanced colorectal carcinoma: preliminary results from KEYNOTE-028. Presented at The European Cancer Congress. Oct. 27, 2015.
37. Rizvi NA, HellmannMD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.
38. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69-74.
39. Lin EI, Tseng LH, Gocke CD, et al. Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget. 2015;6:42334-42344.
40. Kloor M, Becker C, Benner A, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 2005;65:6418-6424.
41. Cabrera CM, Jimenez P, Cabrera T, et al. Total loss ofMHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation inMSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens. 2003;61:211-219.
42. MimaK, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis [published online ahead of print August 26, 2015]. Gut. 2015.